Profile data is unavailable for this security.
About the company
Guerbet SA is a France-based pharmaceutical group specialized in the manufacture and marketing of medical imaging contrast agents destined for diagnostic purposes. It produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents are used in the diagnosis of cardio-vascular, inflammatory and neuro-degenerative disorders. The Company’s portfolio of products comprises brands, such as Xenetix, Hexabrix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol, among others. Guerbet SA is also active in the fine chemicals industry through its Simafex subsidiary. The Company operates through its subsidiaries, including Simafex, Medex, SCI KALB, Guerbet LLC, Guerbet Asie Pacifique and Guerbet GmbH, among others.
- Revenue in EUR (TTM)785.69m
- Net income in EUR23.87m
- Incorporated1968
- Employees2.92k
- LocationGuerbet SA15 rue des Vanesses, Zone Paris Nord IIVILLEPINTE 93420FranceFRA
- Phone+33 145915000
- Fax+33 145915199
- Websitehttps://www.guerbet.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sensorion SA | 0.00 | -22.06m | 218.58m | 50.00 | -- | 4.09 | -- | -- | -0.2063 | -0.2063 | 0.00 | 0.1779 | 0.00 | -- | -- | -- | -51.64 | -35.12 | -71.66 | -46.97 | -- | -- | -- | -- | -- | -- | 0.0794 | -- | -- | -- | 4.94 | -- | 126.45 | -- |
| Nanobiotix SA | 0.00 | -58.78m | 253.58m | 101.00 | -- | -- | -- | -- | -1.68 | -1.68 | 0.00 | -1.53 | 0.00 | -- | -- | 0.00 | -97.14 | -55.16 | -411.11 | -75.16 | -- | -- | -- | -89,710.66 | -- | -6.62 | -- | -- | -100.00 | -- | -21.36 | -- | -42.16 | -- |
| Euroapi SA | 1.02bn | -189.70m | 261.40m | 3.67k | -- | 0.2811 | -- | 0.2566 | -2.01 | -2.01 | 10.73 | 9.78 | 0.6086 | 1.38 | 4.24 | 277,705.10 | -11.34 | -- | -15.93 | -- | 16.15 | -- | -18.63 | -- | 0.6573 | -- | 0.1955 | -- | 3.87 | -- | -1,164.67 | -- | -- | -- |
| Carbios SA | -100.00bn | -100.00bn | 332.87m | 104.00 | -- | 1.42 | -- | -- | -- | -- | -- | 13.92 | -- | -- | -- | -- | -- | -9.92 | -- | -10.77 | -- | -- | -- | -3,365.22 | 9.43 | -- | 0.1719 | -- | -65.71 | -53.32 | 1.86 | -- | -- | -- |
| Medincell SA | 10.85m | -26.42m | 336.06m | 138.00 | -- | -- | -- | 30.98 | -1.02 | -1.02 | 0.4086 | -0.8965 | 0.2605 | -- | 6.81 | 75,853.15 | -63.46 | -59.54 | -115.15 | -117.36 | 60.43 | 68.38 | -243.58 | -451.26 | -- | -4.29 | 1.69 | -- | 141.78 | 8.96 | -29.04 | -- | -2.87 | -- |
| Guerbet SA | 785.69m | 23.87m | 434.22m | 2.92k | 19.10 | 1.15 | 5.21 | 0.5527 | 1.80 | 1.80 | 62.15 | 29.97 | 0.7997 | 0.5983 | 5.80 | 269,071.90 | 2.26 | 1.40 | 2.96 | 1.86 | 78.01 | 76.02 | 2.82 | 1.82 | 1.21 | 5.62 | 0.5035 | 57.82 | 4.30 | -0.0993 | 158.05 | -12.61 | 5.23 | -10.07 |
| Valneva SE | 153.71m | -101.43m | 516.72m | 684.00 | -- | 4.01 | -- | 3.36 | -0.7343 | -0.7343 | 1.11 | 0.924 | 0.2843 | 2.54 | 4.69 | 224,726.60 | -18.76 | -15.39 | -31.44 | -25.06 | 34.37 | 35.94 | -65.99 | -34.95 | 1.37 | -3.57 | 0.6195 | -- | -57.46 | 6.34 | 29.21 | -- | 35.18 | -- |
| Boiron SA | 517.36m | 47.62m | 593.91m | 2.81k | 12.35 | 1.07 | 8.99 | 1.15 | 2.74 | 2.74 | 29.79 | 31.73 | 0.6792 | 1.36 | 6.57 | 184,705.80 | 6.14 | 5.08 | 7.56 | 6.39 | 73.88 | 75.12 | 9.04 | 7.40 | 2.54 | -- | 0.0225 | 48.87 | 17.36 | -2.86 | 56.44 | -10.60 | -19.01 | -7.22 |
| Holder | Shares | % Held |
|---|---|---|
| Financi�re de l'�chiquier SAas of 29 Sep 2023 | 268.66k | 2.13% |
| Healthinvest Partners ABas of 30 Jun 2022 | 250.00k | 1.98% |
| Quaero Capital SAas of 30 Jun 2023 | 202.90k | 1.61% |
| BNP Paribas Asset Management Europe SASas of 28 Mar 2024 | 159.85k | 1.27% |
| HC Capital Advisors GmbHas of 30 Jun 2023 | 151.00k | 1.20% |
| Amundi Asset Management SA (Investment Management)as of 29 Feb 2024 | 149.04k | 1.18% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 117.27k | 0.93% |
| Generali Asset Management SGR SpAas of 30 Dec 2022 | 111.95k | 0.89% |
| Apo Asset Management GmbHas of 30 Sep 2023 | 88.00k | 0.70% |
| Amplegest SASas of 31 Aug 2023 | 87.34k | 0.69% |
